Sodium glucose co-transporter 2 inhibitors for glycemic control in type 2 diabetes mellitus: Quality of reporting of randomized controlled trials
Authors:
Open Access
- 1 January 2016
- journal article
- research article
- Published by Medknow in Perspectives in Clinical Research
- Vol. 7 (1) , 21-7
Abstract
Background: Sodium glucose co-transporter 2 inhibitors represent a novel class of antidiabetic drugs. The reporting quality of the trials evaluating the efficacy of these agents for glycemic control in type 2 diabetes mellitus has not been explored. Our aim was to assess the reporting quality of such randomized controlled trials (RCTs) and to identify the predictors of reporting quality. Materials and Methods: A systematic literature search was conducted for RCTs published till 12 June 2014. Two independent investigators carried out the searches and assessed the reporting quality on three parameters: Overall quality score (OQS) using Consolidated Standards of Reporting Trials (CONSORT) 2010 statement, Jadad score and intention to treat analysis. Inter-rater agreements were compared using Cohen's weighted kappa statistic. Multivariable linear regression analysis was used to identify the predictors. Results: Thirty-seven relevant RCTs were included in the present analysis. The median OQS was 17 with a range from 8 to 21. On Jadad scale, the median score was three with a range from 0 to 5. Complete details about allocation concealment and blinding were present in 21 and 10 studies respectively. Most studies lacked an elaborate discussion on trial limitations and generalizability. Among the factors identified as significantly associated with reporting quality were the publishing journal and region of conduct of RCT. Conclusions: The key methodological items remain poorly reported in most studies. Strategies like stricter adherence to CONSORT guidelines by journals, access to full trial protocols to gain valuable information and full collaboration among investigators and methodologists might prove helpful in improving the quality of published RCT reports.Keywords
This publication has 30 references indexed in Scilit:
- Standards of Medical Care in Diabetes—2014Diabetes Care, 2013
- Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetesBMJ Open, 2012
- Quality of Reporting of Randomized Controlled Trials in General Endocrinology LiteratureThe Journal of Clinical Endocrinology & Metabolism, 2008
- An Official ATS Statement: Grading the Quality of Evidence and Strength of Recommendations in ATS Guidelines and RecommendationsAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort studyBMJ, 2005
- An observational study found that authors of randomized controlled trials frequently use concealment of randomization and blinding, despite the failure to report these methodsJournal of Clinical Epidemiology, 2004
- The CONSORT Statement: Revised Recommendations for Improving the Quality of Reports of Parallel-Group Randomized TrialsAnnals of Internal Medicine, 2001
- The uncertainty principle and industry-sponsored researchThe Lancet, 2000
- What is meant by intention to treat analysis? Survey of published randomised controlled trialsBMJ, 1999
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?The Lancet, 1998